
    
      This is a double blind, randomized (2:1; eszopiclone : placebo), placebo-controlled,
      multicenter, study of eszopiclone in subjects with primary insomnia. The study will involve
      up to 9 visits and subject participation will be approximately 224 days. After meeting all
      screening criteria, subjects will be randomized to either eszopiclone 3 mg QD or placebo.
      This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired
      by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to
      Sunovion Pharmaceuticals Inc.
    
  